|
시장보고서
상품코드
2084911
알레르기성 비염 치료제 시장 : 약제 클래스별, 제형, 투여 경로, 환자 연령층, 처방 유형, 알레르기 유형, 유통 채널별 - 세계 시장 예측(2026-2032년)Allergic Rhinitis Drugs Market by Drug Class, Dosage Form, Route Of Administration, Patient Age Group, Prescription Type, Allergy Type, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
알레르기성 비염 치료제 시장은 2032년까지 연평균 복합 성장률(CAGR) 4.94%로 성장해 73억 1,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 52억 1,000만 달러 |
| 추정 연도(2026년) | 54억 6,000만 달러 |
| 예측 연도(2032년) | 73억 1,000만 달러 |
| CAGR(%) | 4.94% |
알레르기성 비염 치료제 시장에 대한 개요
알레르기성 비염 치료제는 꽃가루, 집먼지, 곰팡이, 동물의 비듬 및 직업성 알레르겐에 노출된 후 발생하는 IgE 매개 염증으로 인해 유발되는 환자 부담이 크고 종종 진단이 누락되기 쉬운 호흡기 질환을 대상으로 합니다. 세계 알레르기 기구 및 ARIA(알레르기성 비염 국제 기준)에 부합하는 문헌에 따르면, 알레르기성 비염은 성인의 약 10%에서 30%, 어린이의 경우 최대 40%에게 영향을 미치는 것으로 보고되고 있습니다. 한편, 세계보건기구(WHO)는 전 세계적으로 4억 명 이상이 알레르기성 비염을 앓으며 생활하고 있다고 지적하고 있습니다.
알레르기성 비염 치료를 재구축하는 혁신적인 변화
알레르기성 비염의 치료 방식은 일시적인 증상 완화에서 정밀한 증상 관리, 복약 순응도가 높은 제형, 그리고 조기 개입으로 점차 전환되고 있습니다. 중등도에서 중증의 질환에 대해서는 비강용 코르티코스테로이드가 여전히 지침에서 권장되는 1차 치료법이지만, 코르티코스테로이드와 항히스타민제를 병용한 복합 스프레이는 서로 보완적인 작용기전을 통해 코막힘, 재채기, 가려움증, 콧물을 개선함으로써 임상적 중요성이 높아지고 있습니다.
알레르기 의료 분야에서 인공지능이 미치는 누적 영향
인공지능(AI)은 알레르기성 비염 치료제 개발, 상용화 및 환자 참여에 점점 더 큰 영향을 미치고 있습니다. 연구 개발 분야에서는 AI를 활용한 분석을 통해 알레르겐 노출 모델링, 환자 계층화, 임상시험 피험자 모집, 의약품 안전성 감시에서의 신호 감지, 그리고 실세계 데이터(REW) 생성을 개선할 수 있습니다. 알레르기성 비염의 경우, 증상이 계절, 지역, 대기 질, 바이러스와의 동시 노출, 그리고 개인의 감작 프로파일에 따라 달라지기 때문에 이러한 적용은 특히 중요합니다.
세계 알레르기 시장의 주요 지역별 분석
아시아태평양은 알레르기성 비염 치료제 시장에서 가장 활기를 띠고 있는 지역 중 하나입니다. 이는 대도시권의 대규모 인구, 대기 오염의 악화, 진드기 및 계절성 꽃가루에 대한 높은 노출, 그리고 중국, 인도, 일본, 한국, 호주, 동남아시아에서의 진단 건수 증가에 기인합니다. 수요는 합리적인 가격의 경구용 항히스타민제, 비강 내 코르티코스테로이드, 복합 스프레이, 알레르겐 면역요법에 이르기까지 다양하며, 이러한 치료법의 보급은 약국 이용 편의성 확대, 대도시권 내 전문 의료 서비스 확충, 그리고 알레르기성 비염이 단순한 재발성 감기가 아니라 만성 염증성 기도 질환이라는 인식의 확산에 의해 형성되고 있습니다.
ASEAN, GCC, EU, BRICS, G7, NATO를 아우르는 주요 그룹 분석
아세안 지역에서는 높은 습도, 실내 알레르기 유발 물질, 교통으로 인한 대기 오염, 그리고 중산층의 의료비 지출 증가로 인해 항히스타민제와 비강 스프레이에 대한 수요가 증가하고 있으며, 이는 알레르기성 비염 치료제 시장에 큰 기회를 제공합니다. 아세안 지역에서 시장 진출은 가격 책정의 유연성, 약국과의 제휴, 의사를 대상으로 한 교육, 그리고 특히 인구 밀도가 높은 도시 지역에서 만성 알레르기성 비염과 일반적인 감기 증상을 구별하기 위한 지역 실정에 맞춘 인식 제고 활동에 달려 있습니다.
주요 알레르기성 비염 치료제 시장의 주요 국가에 대한 인사이트
미국은 일반의약품(OTC) 알레르기 치료제의 상용화, 소비자에 대한 직접적인 인식 제고, 지역 약국에 대한 접근성 향상, 그리고 편의성이 높은 비진정성 치료법의 급속한 보급에 있어 선도적인 위치를 차지하고 있습니다. 한편, 캐나다는 유사한 임상 기준을 갖추고 있으며, 약국 이용이 용이하고, 보험사 측의 영향력도 강하다는 특징이 있습니다. 멕시코와 브라질은 라틴아메리카에서 중요한 알레르기성 비염 치료제 시장으로, 도시 지역의 대기 오염, 꽃가루 노출, 그리고 민간 의료 서비스에 대한 접근성 확대가 경구용 항히스타민제, 비강 내 코르티코스테로이드, 그리고 병용 요법에 대한 수요를 뒷받침하고 있습니다.
알레르기성 비염 분야의 선도 기업을 위한 실천적 제안
업계 리더는 하루 1회 투여하는 비강 스프레이 요법, 즉효성이 있는 항히스타민제, 소아에게 적합한 제제, 코막힘 완화에 대한 명확한 근거가 있는 병용 스프레이 등, 차별화되어 있으며 복약 순응도가 높은 제품을 우선적으로 고려해야 합니다. 또한 각 조직은 OTC로의 전환, 제품 라인 확충, 환자가 사용하기 편리한 투여 기기, 그리고 올바른 비강 스프레이 사용법을 안내하는 포장 및 디지털 교육 등을 통해 제품 수명 주기 관리를 강화해야 합니다.
증거에 기반한 시장 분석을 위한 조사 기법
본 요약본은 2차 조사, 규제 당국의 심사, 임상 지침 평가 및 시장 삼각 측량을 결합한 체계적인 조사 기법에 기반을 두고 있습니다. 검토 대상 정보원에는 세계보건기구(WHO), 세계알레르기기구(WAO), ARIA 지침, 각국의 규제 당국, 임상시험 등록 기관, 동료 심사를 거친 학술지, 제품 라벨 및 공인된 의료 데이터베이스에서 입수 가능한 공개 정보가 포함됩니다.
결론 : 알레르기성 비염 치료제의 전략적 전망
알레르기성 비염 치료제 시장은 환자 중심적이고, 데이터에 기반하며, 지역적으로 다양화된 분야로 진화하고 있습니다. 비강 내 코르티코스테로이드나 2세대 항히스타민제 등 확립된 치료법이 계속해서 임상 치료의 기반을 형성하는 한편, 복합제제, 알레르겐 면역요법, OTC(일반의약품)에 대한 접근성, 그리고 디지털 지원 도구가 차별화를 위한 새로운 기회를 창출하고 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 알레르기성 비염 치료제 시장 : 약제 클래스별
제8장 알레르기성 비염 치료제 시장 : 제형별
제9장 알레르기성 비염 치료제 시장 : 투여 경로별
제10장 알레르기성 비염 치료제 시장 : 환자 연령층별
제11장 알레르기성 비염 치료제 시장 : 처방 유형별
제12장 알레르기성 비염 치료제 시장 : 알레르기 유형별
제13장 알레르기성 비염 치료제 시장 : 유통 채널별
제14장 알레르기성 비염 치료제 시장 : 지역별
제15장 알레르기성 비염 치료제 시장 : 그룹별
제16장 알레르기성 비염 치료제 시장 : 국가별
제17장 경쟁 구도
제18장 기업 개요
KTH 26.07.20The Allergic Rhinitis Drugs Market is projected to grow by USD 7.31 billion at a CAGR of 4.94% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 5.21 billion |
| Estimated Year [2026] | USD 5.46 billion |
| Forecast Year [2032] | USD 7.31 billion |
| CAGR (%) | 4.94% |
Executive Introduction to the Allergic Rhinitis Drugs Market
Allergic rhinitis drugs address a high-burden, frequently underdiagnosed respiratory condition driven by IgE-mediated inflammation after exposure to pollens, dust mites, molds, animal dander, and occupational allergens. The World Allergy Organization and ARIA-aligned literature report allergic rhinitis affecting roughly 10% to 30% of adults and up to 40% of children, while the World Health Organization has referenced more than 400 million people living with allergic rhinitis worldwide.
The therapeutic landscape is anchored by intranasal corticosteroids, second-generation oral and intranasal antihistamines, leukotriene receptor antagonists, decongestants, mast-cell stabilizers, anticholinergic nasal sprays, saline products, and allergen immunotherapy. Demand is supported by rising aeroallergen exposure, urban air pollution, climate-driven changes in pollen season timing and intensity, consumer preference for non-sedating therapies, and expanding over-the-counter access for established allergy medicines.
Transformative Shifts Reshaping Allergic Rhinitis Treatment
The allergic rhinitis treatment landscape is shifting from episodic symptom relief toward precision symptom control, adherence-friendly formulations, and earlier intervention. Intranasal corticosteroids remain guideline-supported first-line therapy for moderate-to-severe disease, but combination sprays that pair corticosteroids with antihistamines are gaining clinical relevance by addressing congestion, sneezing, itching, and rhinorrhea through complementary mechanisms.
A major structural shift is the growing role of self-care. Regulatory switches from prescription to over-the-counter status, including intranasal antihistamine and corticosteroid products in several mature markets, have expanded pharmacy-led access and intensified brand and generic competition. At the same time, sublingual and subcutaneous allergen immunotherapy continue to differentiate the market by targeting disease modification rather than short-term symptom suppression, particularly for patients with confirmed allergen sensitization and persistent symptoms.
Cumulative Impact of Artificial Intelligence on Allergy Care
Artificial intelligence is increasingly influencing allergic rhinitis drug development, commercialization, and patient engagement. In research and development, AI-supported analytics can improve allergen exposure modeling, patient stratification, trial recruitment, pharmacovigilance signal detection, and real-world evidence generation. These applications are especially relevant for allergic rhinitis because symptoms fluctuate by season, geography, air quality, viral co-exposures, and individual sensitization profile.
Commercially, AI-enabled digital health tools are helping connect pollen counts, weather data, symptom diaries, medication use, and adherence reminders. The cumulative impact is a move toward personalized allergy management, where drug selection and timing can be guided by predictive exposure insights. However, responsible adoption requires transparent algorithms, privacy safeguards, clinically validated outputs, and alignment with medical device, consumer health, and health data regulations.
Key Regional Insights Across Global Allergy Markets
Asia-Pacific is one of the most dynamic regions for allergic rhinitis drugs, supported by large urban populations, worsening air pollution, high exposure to dust mites and seasonal pollens, and rising diagnosis in China, India, Japan, South Korea, Australia, and Southeast Asia. Demand spans affordable oral antihistamines, intranasal corticosteroids, combination sprays, and allergen immunotherapy, with adoption shaped by expanding pharmacy access, stronger specialist care in metropolitan centers, and increasing recognition of allergic rhinitis as a chronic inflammatory airway disorder rather than a recurring cold.
North America remains a high-value allergic rhinitis drugs landscape due to broad OTC availability, strong payer and retail pharmacy infrastructure, high consumer awareness, and established use of branded and generic therapies. Europe benefits from guideline-driven care, strong regulatory oversight, pharmacovigilance requirements, and advanced immunotherapy adoption, while Latin America shows steady demand led by Brazil and Mexico as access to allergy specialists, private healthcare, and modern nasal therapies improves in urban centers.
The Middle East is gaining relevance as dust exposure, indoor allergens, air-conditioning use, and urbanization drive chronic rhinitis symptoms, particularly in GCC countries with higher private healthcare utilization and specialist access. Africa remains heterogeneous, with unmet diagnostic capacity, affordability constraints, and variable availability of intranasal therapies; however, long-term opportunity is supported by urban growth, pharmacy expansion, and increasing recognition of allergic airway disease across primary care systems.
Key Group Insights Covering ASEAN, GCC, EU, BRICS, G7, and NATO
ASEAN presents a high-volume opportunity for allergic rhinitis drugs as humid climates, indoor allergens, traffic pollution, and expanding middle-class healthcare spending increase demand for antihistamines and nasal sprays. Market execution in ASEAN depends on pricing flexibility, pharmacy partnerships, physician education, and localized awareness that helps distinguish persistent allergic rhinitis from common-cold symptoms, particularly in densely populated urban settings.
The GCC is characterized by premium healthcare infrastructure, high private-sector participation, and environmental exposure to desert dust, indoor allergens, and air-conditioning-related irritants. The European Union provides a mature regulatory and access environment where evidence-based guidelines, pharmacovigilance, substitution policies, and generics shape competition, while allergen immunotherapy maintains a stronger clinical foothold than in many emerging markets due to specialist networks and standardized product oversight.
BRICS markets combine scale and complexity, with China and India providing major volume potential through urbanization and pollution-related respiratory burden, Brazil supporting regional leadership in Latin America, and Russia reflecting demand for established therapies amid access, pricing, and supply-chain considerations. G7 markets remain innovation and commercialization centers due to advanced reimbursement systems, strong retail channels, high use of non-sedating therapies, and earlier adoption of patient-support tools. NATO countries overlap substantially with North American and European allergy markets, where supply resilience, regulatory quality, domestic availability of essential respiratory medicines, and continuity of care are increasingly important strategic priorities.
Key Country Insights in Major Allergic Rhinitis Drug Markets
The United States leads in OTC allergy drug commercialization, direct-to-consumer education, community pharmacy access, and rapid uptake of convenient non-sedating treatments, while Canada shows similar clinical standards with strong pharmacy access and payer influence. Mexico and Brazil represent important Latin American allergic rhinitis drug markets where urban pollution, pollen exposure, and expanding private healthcare access support demand for oral antihistamines, intranasal corticosteroids, and combination therapies.
In Europe, the United Kingdom, Germany, France, Italy, and Spain demonstrate mature allergic rhinitis management supported by clinical guidelines, established generics, community pharmacy involvement, and growing attention to quality-of-life burden. Germany and France are particularly relevant for evidence-led prescribing and immunotherapy expertise, while the United Kingdom has strong community pharmacy participation and self-care pathways. Russia remains a sizable market for established allergy medications, although access dynamics can be affected by pricing, regulation, reimbursement practices, and supply-chain conditions.
China and India are major growth engines due to population scale, urbanization, air pollution, expanding middle-class healthcare spending, and increasing specialist diagnosis. Japan has a sophisticated allergy market shaped by cedar pollen disease burden, high consumer awareness, and strong use of prescription and OTC options, while South Korea combines advanced healthcare access with demand for modern nasal and oral therapies. Australia remains important due to high allergic disease prevalence, strong primary care engagement, and seasonal pollen-related demand, including heightened attention to thunderstorm asthma risk in sensitized populations.
Actionable Recommendations for Allergic Rhinitis Industry Leaders
Industry leaders should prioritize differentiated, adherence-friendly products, including once-daily intranasal therapies, rapid-onset antihistamines, pediatric-appropriate formulations, and combination sprays with clear evidence for nasal congestion relief. Organizations should also strengthen lifecycle management through OTC switches, line extensions, patient-friendly delivery devices, and packaging or digital education that supports correct nasal spray technique.
Commercial strategy should combine physician education, pharmacist engagement, and digital symptom tracking tied to pollen and air-quality alerts. In emerging markets, success depends on tiered pricing, reliable distribution, and disease-awareness campaigns that distinguish allergic rhinitis from viral respiratory symptoms. Across all markets, manufacturers should invest in real-world evidence, pharmacovigilance, validated AI tools, and patient-reported outcomes to demonstrate symptom control, adherence, safety, and quality-of-life improvement.
Research Methodology for Evidence-Based Market Analysis
This executive summary is based on a structured research methodology combining secondary research, regulatory review, clinical guideline assessment, and market triangulation. Sources considered include publicly available information from the World Health Organization, World Allergy Organization, ARIA guidance, national regulatory agencies, clinical trial registries, peer-reviewed journals, product labels, and recognized healthcare databases.
The analysis evaluates drug classes, route of administration, prescription and OTC dynamics, regional access patterns, disease prevalence indicators, regulatory approvals, treatment guideline positioning, and competitive positioning by therapy type. Insights are validated through cross-comparison of epidemiology, treatment guidelines, market availability, product labeling, and real-world adoption signals to ensure the conclusions remain evidence-led, commercially relevant, and suitable for strategic decision-making without relying on market sizing or forecasting.
Conclusion: Strategic Outlook for Allergic Rhinitis Drugs
The allergic rhinitis drugs market is evolving into a more patient-centered, data-informed, and regionally diversified sector. Established therapies such as intranasal corticosteroids and second-generation antihistamines will continue to form the clinical backbone, while combination products, allergen immunotherapy, OTC access, and digital support tools create new opportunities for differentiation.
Future industry momentum will be shaped by climate-related allergen exposure, urban air pollution, consumer self-care behavior, regulatory decisions on access, and the ability of suppliers to prove real-world value. Organizations that combine strong clinical evidence, accessible pricing, reliable supply, responsible digital engagement, and personalized patient support will be best positioned to address demand across mature and emerging allergic rhinitis drug markets.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Allergic Rhinitis Drugs Market, by Drug Class
- 7.1. Decongestants
- 7.1.1. Phenylephrine
- 7.1.2. Pseudoephedrine
- 7.2. H1 Antihistamines
- 7.2.1. First Generation
- 7.2.2. Second Generation
- 7.3. Intranasal Corticosteroids
- 7.3.1. Budesonide
- 7.3.2. Fluticasone
- 7.3.3. Mometasone
- 7.3.4. Triamcinolone
- 7.4. Leukotriene Receptor Antagonists
- 7.4.1. Montelukast
- 7.4.2. Zafirlukast
- 7.5. Mast Cell Stabilizers
- 7.5.1. Cromolyn Sodium
- 7.5.2. Nedocromil
8. Allergic Rhinitis Drugs Market, by Dosage Form
- 8.1. Eye Drop
- 8.1.1. Multi Use
- 8.1.2. Single Use
- 8.2. Injection
- 8.2.1. Intramuscular
- 8.2.2. Subcutaneous
- 8.3. Nasal Spray
- 8.3.1. Dry Powder
- 8.3.2. Metered Dose
- 8.4. Oral Solution
- 8.4.1. Liquid Concentrate
- 8.4.2. Ready To Use
- 8.5. Tablet
- 8.5.1. Extended Release
- 8.5.2. Immediate Release
9. Allergic Rhinitis Drugs Market, by Route Of Administration
- 9.1. Nasal
- 9.2. Ocular
- 9.3. Oral
- 9.4. Parenteral
- 9.4.1. Intramuscular
- 9.4.2. Intravenous
- 9.4.3. Subcutaneous
10. Allergic Rhinitis Drugs Market, by Patient Age Group
- 10.1. Adult
- 10.2. Geriatric
- 10.3. Pediatric
11. Allergic Rhinitis Drugs Market, by Prescription Type
- 11.1. Prescription Drugs
- 11.2. Over-the-Counter
12. Allergic Rhinitis Drugs Market, by Allergy Type
- 12.1. Seasonal Allergic Rhinitis
- 12.2. Perennial Allergic Rhinitis
- 12.3. Occupational Allergic Rhinitis
13. Allergic Rhinitis Drugs Market, by Distribution Channel
- 13.1. Online Pharmacy
- 13.2. Offline Pharmacy
- 13.2.1. Hospital Pharmacy
- 13.2.2. Retail Pharmacy
- 13.2.3. Specialty Pharmacy
14. Allergic Rhinitis Drugs Market, by Region
- 14.1. Asia-Pacific
- 14.2. North America
- 14.3. Latin America
- 14.4. Europe
- 14.5. Middle East
- 14.6. Africa
15. Allergic Rhinitis Drugs Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
16. Allergic Rhinitis Drugs Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
17. Competitive Landscape
- 17.1. Market Concentration Analysis, 2025
- 17.1.1. Concentration Ratio (CR)
- 17.1.2. Herfindahl Hirschman Index (HHI)
- 17.2. Recent Developments & Impact Analysis, 2025
- 17.3. Product Portfolio Analysis, 2025
- 17.4. Benchmarking Analysis, 2025
18. Company Profiles
- 18.1. ALK-Abello A/S
- 18.2. Allergy Therapeutics PLC
- 18.3. Apotex Inc.
- 18.4. AstraZeneca PLC
- 18.5. Aurobindo Pharma Limited
- 18.6. Bausch Health Companies Inc.
- 18.7. Bayer AG
- 18.8. Boehringer Ingelheim International GmbH
- 18.9. Cadila Pharmaceuticals Limited
- 18.10. Cipla Limited
- 18.11. Dr. Reddy's Laboratories Ltd.
- 18.12. GlaxoSmithKline PLC
- 18.13. Glenmark Pharmaceuticals Ltd.
- 18.14. Hikma Pharmaceuticals PLC
- 18.15. Johnson & Johnson Services, Inc.
- 18.16. Lupin Limited
- 18.17. Merck & Co., Inc.
- 18.18. Novartis AG
- 18.19. Perrigo Company plc
- 18.20. Pfizer Inc.
- 18.21. Sanofi S.A.
- 18.22. Stallergenes Greer International AG
- 18.23. Sumitomo Pharma Group
- 18.24. Sun Pharmaceutical Industries Ltd.
- 18.25. Teva Pharmaceutical Industries Ltd.
- 18.26. UCB S.A.
- 18.27. Unichem Laboratories Limited
- 18.28. Viatris Inc.
